EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study

Bin Chu, Yu-Tong Wang, Shan Gao, Lei Shi, Min-Qiu Lu, Li-Juan Fang, Qiu-Qing Xiang, Yuan Chen, Meng-Zhen Wang, Li-Fang Wang, Kai Sun, Jing Yang und 2 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05806-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Bin Chu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Beijing Jishuitan Hospital, Capital Medical University, No. 31 East Xinjiekou Street, Xicheng District, Beijing, 100035, Ch…. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm Staging, Plasma Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Natural Science Foundation, Yangfan plan of Beijing Hospitals Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to evaluate if circulating plasma cells (CPC) detected by flow cytometry could add prognostic value of R2-ISS staging. We collected the electronic medical records of 336 newly diagnosed MM patients (NDMM) in our hospital from January 2017 to June 2023. The median overall survival (OS) for patients and R2-ISS stage I-IV were not reached (NR), NR, 58 months and 53 months, respectively. There was no significant difference in OS between patients with stage I and patients with stage II ( P = 0.309) or between patients with stage III and patients with stage IV ( P = 0.391). All the cases were re-classified according to R2-ISS stage and CPC numbers ≥ 0.05% (CPC high) or

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaNeoplasm StagingPlasma CellsHumansFemaleMaleMiddle AgedAgedAdultRisk AssessmentAged, 80 and overRetrospective StudiesSurvival RatePrognosisFlow CytometryNeoplastic Cells, Circulating

Stichwörter der Autor:innen

Circulating plasma cellMultiple myelomaOverall survivalPrognosisR2-ISS stage

Autor:innen und Institutionen

  • Department of Hematology, Beijing Jishuitan Hospital, Capital Medical University, No. 31 East Xinjiekou Street, Xicheng District, Beijing, 100035, China.
  • Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, 77030, USA.
  • Clinical Epidemiology Research Center, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.
  • Department of Hematology, Beijing Jishuitan Hospital, Capital Medical University, No. 31 East Xinjiekou Street, Xicheng District, Beijing, 100035, China. baolilq909@sina.com.

Förderung

  • Beijing Municipal Natural Science Foundation
  • Yangfan plan of Beijing Hospitals Authority

Zitieren

APA

Chu, B., Wang, Y. T., Gao, S., Shi, L., Lu, M. Q., Fang, L. J., Xiang, Q. Q., Chen, Y., Wang, M. Z., Wang, L. F., Sun, K., Yang, J., Duan, F., & Bao, L. (2024). R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05806-9

Vancouver

Chu B, Wang YT, Gao S, Shi L, Lu MQ, Fang LJ, et al. R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05806-9

BibTeX
@article{Chu2024,
  author = {Chu, Bin and Wang, Yu-Tong and Gao, Shan and Shi, Lei and Lu, Min-Qiu and Fang, Li-Juan and Xiang, Qiu-Qing and Chen, Yuan and Wang, Meng-Zhen and Wang, Li-Fang and Sun, Kai and Yang, Jing and Duan, Fangfang and Bao, Li},
  title = {R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05806-9}
}
Kostenlos starten →